• Home
  •  / Tonix Pharmaceuticals

Tonix Pharmaceuticals

OverviewSuggest Edit

Tonix Pharmaceuticals is a development stage specialty pharmaceutical company, which focuses on the development of pharmaceutical products for the disorders of central nervous system. The Company's lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. Tonix is also developing TNX-601, a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder; and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage.

TypePublic
Founded2007
HQNew York, USMap
Websitetonixpharma.com

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2019)12(-14%)
Share Price (Jul 2020)$0.7
Cybersecurity ratingAMore

Key People/Management at Tonix Pharmaceuticals

Seth Lederman

Seth Lederman

Co-Founder, CEO & Chairman
Jessica Edgar Morris

Jessica Edgar Morris

Chief Operating Officer
Margaret Smith Bell

Margaret Smith Bell

Director
Gregory Sullivan

Gregory Sullivan

Chief Medical Officer
Daniel Goodman

Daniel Goodman

Director
Bradley Saenger

Bradley Saenger

Chief Financial Officer
Show more

Tonix Pharmaceuticals Office Locations

Tonix Pharmaceuticals has offices in New York, San Diego, Montréal and Dublin
New York, US (HQ)
509 Madison Ave
San Diego, US
4225 Executive Square #250, La Jolla
Montréal, CA
317 1176 Rue Bishop
Dublin, IE
56 Fitzwilliam Square N
Show all (4)

Tonix Pharmaceuticals Financials and Metrics

Tonix Pharmaceuticals Revenue

USD

Net income (Q1, 2020)

(7.3m)

EBIT (Q1, 2020)

(7.3m)

Market capitalization (9-Jul-2020)

36.0m

Closing stock price (9-Jul-2020)

0.7

Cash (31-Mar-2020)

30.7m

EV

5.9m
Tonix Pharmaceuticals's current market capitalization is $36 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

2.2m4.1m6.2m9.0m12.7m10.4m7.9m8.8m10.6m

R&D expense

1.2m2.6m4.7m18.6m35.5m28.5m13.3m17.6m18.2m

Operating expense total

3.4m6.7m10.9m27.7m48.2m39.0m21.3m26.3m28.8m

EBIT

(3.4m)(6.7m)(10.9m)(27.7m)(48.2m)(39.0m)(21.3m)(26.3m)(28.8m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

General and administrative expense

316.01.1k762.7k1.0m1.1m1.3m1.1m1.6m2.0m2.2m2.9m2.9m3.0m3.3m2.3m2.1m2.1m2.0m1.9m1.8m2.1m2.3m2.4m2.4m2.8m2.6m

R&D expense

397.6k827.8k658.1k740.6k944.0k3.6m4.1m5.2m6.8m8.9m10.3m10.7m7.5m5.5m3.0m2.8m3.9m5.2m4.1m3.3m3.9m3.6m5.1m4.7m

Operating expense total

316.01.1k1.2m1.9m1.7m2.0m2.1m5.2m6.0m7.4m9.7m11.8m13.3m14.0m9.8m7.6m5.1m4.8m5.8m7.0m6.1m5.5m6.3m5.9m7.9m7.3m

Depreciation and amortization

5.0k
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

41.1k1.8m8.2m38.2m19.2m18.9m25.5m25.0m11.2m

Accounts Receivable

598.6m

Prepaid Expenses

102.4k224.7k429.0k852.0k3.3m947.0k1.0m2.7m

Current Assets

143.6k2.0m8.6m39.0m46.4m27.1m26.4m26.1m13.9m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

747.0205.02.5m1.3m35.7k423.7k68.0k7.4m49.5m43.9m46.2m58.2m48.7m33.0m8.4m14.9m15.6m19.9m34.4m29.3m19.3m16.7m14.7m16.4m12.2m10.0m30.7m

Prepaid Expenses

64.0k74.5k43.1k67.7k46.4k46.4k554.0k946.0k699.0k1.8m1.6m2.1m3.2m2.4m2.5m1.0m1.1m896.0k1.4m1.4m1.1m2.7m2.0m1.5m2.7m

Current Assets

2.6m1.4m78.7k491.4k114.4k7.5m50.1m44.8m46.9m60.0m50.3m57.2m30.7m33.7m29.2m23.4m35.5m30.2m20.7m18.2m15.9m19.2m14.2m11.6m33.4m

PP&E

23.2k53.2k51.0k42.8k38.8k42.8k43.0k71.0k224.0k306.0k316.0k327.0k383.0k349.0k315.0k132.0k118.0k102.0k78.0k65.0k55.0k41.0k36.0k34.0k28.0k
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.5m)(9.4m)(10.9m)(27.6m)(48.1m)(38.8m)(21.1m)(26.1m)(28.6m)

Depreciation and Amortization

9.3k14.3k17.0k36.0k161.0k339.0k70.0k54.0k26.0k

Accounts Payable

377.5k130.6k(60.0k)728.0k1.6m(2.2m)424.0k106.0k1.7m

Cash From Operating Activities

(2.6m)(5.7m)(8.5m)(22.8m)(42.5m)(37.3m)(19.1m)(24.0m)(26.7m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(1.5k)(2.3k)(2.0m)(5.1m)(6.8m)(2.0m)(4.1m)(7.2m)(5.2m)(11.2m)(18.6m)(9.7m)(21.4m)(34.7m)(14.0m)(23.8m)(31.4m)(5.1m)(9.8m)(15.6m)(6.9m)(13.0m)(18.5m)(6.2m)(12.1m)(19.9m)(7.3m)

Depreciation and Amortization

2.4k6.1k10.2k4.1k8.1k12.2k4.0k9.0k15.0k22.0k45.0k90.0k57.0k113.0k163.0k24.0k34.0k50.0k15.0k30.0k43.0k9.0k16.0k21.0k6.0k

Accounts Payable

(512.8k)(208.3k)2.2k44.3k635.4k160.0k635.0k754.0k1.7m502.0k1.3m948.0k(986.0k)(1.1m)(2.1m)(31.0k)307.0k490.0k(32.0k)342.0k(249.0k)(270.0k)(358.0k)(285.0k)(1.7m)

Cash From Operating Activities

(1.8m)(2.9m)(4.2m)(1.4m)(2.1m)(5.0m)(4.1m)(9.8m)(14.6m)(9.1m)(18.3m)(30.6m)(15.5m)(23.5m)(31.9m)(4.8m)(9.2m)(14.2m)(6.8m)(12.3m)(17.1m)(8.6m)(13.4m)(20.0m)(9.3m)
show all
USDQ2, 2011

Financial Leverage

-0.1 x
Show all financial metrics

Tonix Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

Learn more about about our premium products
SecurityScorecard logo

Tonix Pharmaceuticals Online and Social Media Presence

Tonix Pharmaceuticals's Trends

Embed Graph

Tonix Pharmaceuticals News and Updates

July 10, 2020

Tonix Pharmaceuticals Completes Enrollment in Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia

Target Enrollment Completed Ahead of Schedule
June 18, 2020

Thinking about buying stock in Tonix Pharmaceuticals, Alpine Immune Sciences, Allied Esports Entertainment, Boxlight Corp, or United States Steel?

NEW YORK, June 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TNXP, ALPN, AESE, BOXL, and X. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
June 17, 2020

Tonix Pharmaceuticals Announces that Results from Preclinical Studies of TNX-1700 Will be Presented in a Poster at the AACR Virtual Annual Meeting 2020

NEW YORK, June 17, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that preclinical results of TNX-1700 (rTFF2) will be presented in a poster at the American Association of Cancer Resear…
June 10, 2020

Tonix Pharmaceuticals Announces Appointment of Richard H. Bagger to Board of Directors

NEW YORK, June 10, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Richard H. Bagger to its Board of Directors, effective as of June 9, 2020. Mr. Bagger assumes the se…
June 03, 2020

Tonix Pharmaceuticals to Participate in Two June Virtual Investor Conferences

NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will participate and host one-on-one meetings at two virtual investor conferences in June.
May 21, 2020

Tonix Pharmaceuticals Posted Results from Pharmacokinetic Analyses of TNX-102 SL and TNX-601 CR in Advance of Virtual Poster Presentations at the American Society of Clinical Psychopharmacology

NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, posted two posters for the American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting to be held online virtually on May…
Show more

Tonix Pharmaceuticals Blogs

May 19, 2020

Tonix Pharmaceuticals Announces Appointment of Herbert Harris, M.D., Ph.D., as Executive Vice President, Translational Medicine

NEW YORK, May 19, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Herbert Harris, M.D., Ph.D., as its new Executive Vice President, Translational Medicine, effective M…
May 12, 2020

Tonix Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights

Four Potential Vaccines in Development to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on the Company’s Horsepox Virus Vaccine Platform Potential Vaccine, TNX-801, in Development to Protect Against Smallpox and Monkeypox Based on Horsepox Virus Achieves 50 Percent Enrollment in P…
May 07, 2020

Tonix Pharmaceuticals Enters into Research Collaboration and Exclusive License Agreement with University of Alberta to Develop Novel Horsepox-Based Vaccines, TNX-1810, TNX-1820 and TNX-1830, for the Prevention of COVID-19

TNX-1810, TNX-1820 and TNX-1830 are Designed to Express Protein Antigens from SARS-CoV-2 That are Different from TNX-1800, Which is Designed to Express Spike Protein NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-st…
April 24, 2020

Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia

Enrollment Continues in Phase 3 RELIEF Study, with Interim Results of the First 50 Percent of Participants Expected in September 2020 Topline Results of Approximately 470 Participants with Fibromyalgia Expected in the First Quarter of 2021 NEW YORK, April 24, 2020 (GLOBE NEWSWIRE) -- Tonix Phar…
March 24, 2020

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

Potential Vaccine, TNX-1800 in Development to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on the Company’s Horsepox Virus Vaccine Platform Potential Vaccine, TNX-801 in Development to Protect Against Smallpox and Monkeypox Based on Horsepox Virus Interim Analysis Results for Pha…
March 23, 2020

Tonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor Summit

NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will be conducting a virtual presentation in conjunction with the Spring Investor Summit …
Show more

 Tonix Pharmaceuticals Frequently Asked Questions

  • When was Tonix Pharmaceuticals founded?

    Tonix Pharmaceuticals was founded in 2007.

  • Who are Tonix Pharmaceuticals key executives?

    Tonix Pharmaceuticals's key executives are Seth Lederman, Jessica Edgar Morris and Margaret Smith Bell.

  • How many employees does Tonix Pharmaceuticals have?

    Tonix Pharmaceuticals has 12 employees.

  • Who are Tonix Pharmaceuticals competitors?

    Competitors of Tonix Pharmaceuticals include ThermoGenesis, Savara Pharmaceuticals and XtalPi.

  • Where is Tonix Pharmaceuticals headquarters?

    Tonix Pharmaceuticals headquarters is located at 509 Madison Ave, New York.

  • Where are Tonix Pharmaceuticals offices?

    Tonix Pharmaceuticals has offices in New York, San Diego, Montréal and Dublin.

  • How many offices does Tonix Pharmaceuticals have?

    Tonix Pharmaceuticals has 4 offices.